Aura Biosciences, Inc. Cash and Restricted Cash
Aura Biosciences, Inc. (AURA) had Cash and Restricted Cash of $68.60 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $68.60M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85.56M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60.28M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48.32M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $68.60M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $85.56M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $60.28M 10-K · filed 2026-03-30 |
| 2025-09-30 | $48.32M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $108.14M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $38.99M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $32.46M 10-K · filed 2026-03-30 |
| 2024-09-30 | $26.18M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $30.84M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $27.05M 10-Q · filed 2025-05-15 |
| 2023-12-31 | $41.85M 10-K · filed 2025-03-24 |
| 2023-09-30 | $56.37M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $48.52M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $39.28M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $122.37M 10-K · filed 2024-03-27 |
| 2022-09-30 | $62.06M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $54.77M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $108.53M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $149.21M 10-K · filed 2023-03-15 |
| 2021-09-30 | $81.97M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $92.35M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $99.77M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $17.49M 10-K · filed 2022-03-23 |
| 2020-09-30 | $16.24M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |